Role of adipokines and cytokines in non-alcoholic fatty liver disease

Reviews on Recent Clinical Trials

Volumn 9, Issue 3, 2014, Pages 134-140

  Abenavoli, Ludovico ^a   Peta, Valentina ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Adipokines; Cytokines; Fibrosis; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Steatosis

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CYTOKINE; INTERLEUKIN 6; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BROWN ADIPOSE TISSUE; DOWN REGULATION; GENE EXPRESSION; HUMAN; LIPOGENESIS; MOLECULAR WEIGHT; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; WHITE ADIPOSE TISSUE; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYSIOLOGY;

ADIPOKINES; CYTOKINES; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84922334179     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887109666141216102458     Document Type: Article

References (97)

1. [1] Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28(1): 155-61.
2. [2] Nascimbeni F, Pais R, Bellentani S, et al. From nafld in clinical practice to answers from guidelines. J Hepatol 2013; 59(4): 859-71.
3. [3] Yilmaz Y. Is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 2012; 36(9): 815-23.
4. [4] Abenavoli L, Milic N, Masarone M, Persico M. Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. Med Hypotheses 2013; 81(5): 913-5.
5. [5] Loria P, Adinolfi LE, Bellentani S, et al. NAFLD Expert Committee of the Associazione Italiana per lo studio del Fegato. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010; 42(4): 272-82.
6. [6] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142(7): 1592-609.
7. [7] Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006; 44: 466-71.
8. [8] Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study. Hepatology 2005; 42: 44-52.
9. [9] Bedogni G, Miglioli L, Masutti F, et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007; 46: 1387-91.
10. [10] Abenavoli L, Bellentani S. Milk thistle to treat non-alcoholic fatty liver disease: dream or reality? Expert Rev Gastroenterol Hepatol 2013; 7(8): 677-9.
11. [11] Smith BW, Adams LA. Non-alcoholic fatty liver disease. Clin Lab Sci 2011; 48(3): 97-113.
12. [12] Milic S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 2012; 30(2): 158-62.
13. [13] Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114(4): 842-5.
14. [14] Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009; 41(9): 615-25.
15. [15] Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-112.
16. [16] Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42: 987-1000.
17. [17] Arner P. Insulin resistance in type 2 diabetes – role of the adipokines. Curr Mol Med 2005; 5: 333-9.
18. [18] Lemoine M, Ratziu V, Kim M, et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver diseas. Liver Int 2009; 29(9): 1431-38.
19. [19] Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009; 54(9): 1847-56.
20. [20] Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92(3): 347-55.
21. [21] Trayhurn P, Wood IS. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans 2005; 33: 1078-81.
22. [22] Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-19.
23. [23] Mulhall BP, Ong JP, Younossi ZM. Nonalcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 2002; 17: 1136-43.
24. [24] Lutchman G, Promrat K, Kleiner DE, et al. Changes in serum adipokine levels steatohepatitis: relationship to histological improve ment. Clin Gastroenterol Hepatol 2006; 4: 104-52.
25. [25] Kumar R, Prakash S, Chhabra S, et al. Association of proinflammatory cytokines, adipokines & oxidative stress with insulin resistance & non-alcoholic fatty liver disease. Indian J Med Res 2012; 136(2): 229-36.
26. [26] Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27(5): 412-21.
27. [27] Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. CDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-9.
28. [28] Waki H, Yamauchi T, Kamon J, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 278(41): 40352-63.
29. [29] Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in nonalcoholic steatohepatitis. Gut 2005; 54: 117-21.
30. [30] Tsao TS, Lodish HF, Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 2002; 440(2-3): 213-21.
31. [31] Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adiposespecific protein, adiponectin, in obesity. Biochem Biophys Res Commun 2012; 425(3): 560-4.
32. [32] Abenavoli L. Adiponectin levels in nonalcoholic fatty liver disease. Metabolism 2011; 60(12): e3.
33. [33] Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V, Murphy BD, Palin MF. Adiponectin action from head to toe. Endocrine 2010; 37(1): 11-32.
34. [34] Lautamäki R, Rönnemaa T, Huupponen R, et al. Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism 2007; 56(7): 881-6.
35. [35] Kazumi T, Kawaguchi A, Hirano T, Yoshino G. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. Metabolism 2004; 53(5): 589-93.
36. [36] Christou GA, Tellis KC, Elisaf MC, Tselepis AD, Kiortsis DN. High density lipoprotein is positively correlated with the changes in circulating total adiponectin and high molecular weight adiponectin during dietary and fenofibrate treatment. Hormones 2012; 11(2): 178-88.
37. [37] Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004; 323(2): 630-5.
38. [38] Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423(6941): 762-9.
39. [39] Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98: 2005-10.
40. [40] Yamauchi T, Kamon J, Waki H, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE deficient mice from atherosclerosis. J Biol Chem 2003; 278: 2461-8.
41. [41] Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116(7): 1784-92.
42. [42] Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMPactivated protein kinase. Nat Med 2002; 8(11): 1288-95.
43. [43] Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54.
44. [44] Musso G, Gambino R, Biroli G, et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pan-creatic Beta-cell dysfunction in nondiabeticnonobese patients withnonalcoholicsteatohepatitis. Am J Gastroenterol 2005; 100: 2438-46.
45. [45] Targher G, Bertolini L, Scala L, Poli F, Zenari L, Falezza G. Decreased plasma adiponectin concentrations are closely associated withnonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol 2004; 61: 700-3.
46. [46] Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60(3): 313-26.
47. [47] Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54(1): 117-21.
48. [48] Aller R, de Luis DA, Fernandez L, et al. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig Dis Sci 2008; 53: 1088-92.
49. [49] Targher G, Bertolini L, Rodella S, et al. Associations between plasmaadiponectin concentrations and liver histology in patients withnonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006; 64: 679-83.
50. [50] Musso G, Gambino R, De Michieli F, et al. Association of liver disease with postprandiallarge intestinal triglyceride-rich lipoprotein accumulation andpro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis. Ann Med 2008; 40: 383-94.
51. [51] Abenavoli L, Luigiano C, Guzzi PH, et al. Serum adipokine levels in overweight patients and their relationship with non-alcoholic fatty liver disease. Panminerva Med 2014; 56(2): 189-93.
52. [52] Zelber-Sagi S, Ratziu V, Zvibel I, et al. The association between adipocytokines and biomarkers for nonalcoholic fatty liver diseaseinduced liver injury: a study in the general population. Eur J Gastroenterol Hepatol 2012; 24: 262-9.
53. [53] Shimada M, Kawahara H, Ozaki K, et al. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7 S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 2007; 102: 1931-8.
54. [54] Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for obesity-related non-alcoholic steatohepatitis (NASH). Obes Surg 2008; 18: 1430-7.
55. [55] Tietge UJ, Boker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004; 287: 82-9.
56. [56] Kaser S, Moschen A, Kaser A, et al. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med 2005; 258: 274-80.
57. [57] Bodles AM, Banga A, Rasouli N, Ono F, Kern PA, Owens RJ. Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab 2006; 291(5): E1100-05.
58. [58] Rasouli N, Yao-Borengasser A, Miles LM, Elbein SC, Kern PA. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab 2006; 290(1): E42-6.
59. [59] Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. Clin Invest 1998; 101(6): 1354-61.
60. [60] Furuhashi M, Ura N, Higashiura K, et al. Blockade of the reninangiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42(1): 76-81.
61. [61] Xu A, Wang H, Hoo RL, et al. Selective elevation of adiponectin production by the natural compounds derived from a medicinal herb alleviates insulin resistance and glucose intolerance in obese mice. Endocrinology 2009; 150(2): 625-33.
62. [62] Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 2009; 30(5): 234-9.
63. [63] Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372(6505): 425-32.
64. [64] Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002; 26(11): 1407-33.
65. [65] Gualillo O, Eiras S, Lago F, Dieguez C, Casanueva FF. Elevated serum leptin concentrations induced by experimental acute inflammation. Life Sci 2000; 67: 2433-41.
66. [66] Blum WF, Englaro P, Hanitsch S, et al. Plasma leptin levels in healthy children and adolescents: dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. Clin Endocrinol Metab 1997; 82: 2904-10.
67. [67] Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008; 70: 537-56.
68. [68] Lebensztejn DM, Wojtkowska M, Skiba E, Werpachowska I, Tobolczyk J, Kaczmarski M. Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease. Adv Med Sci 2009; 54(2): 177-82.
69. [69] Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006; 101(11): 2629-40.
70. [70] Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB J 1998; 12(1): 57-65.
71. [71] Javor ED, Ghany MG, Cochran EK, et al. Leptin reverses nonalcoholicsteatohepatitis in patients with severe lipodystrophy. Hepatology 2005; 41: 753-60.
72. [72] Kusminski CM, McTernan PG, Kumar S. Role of resistin in obesity, insulin resistance and Type II. Clin Sci (Lond) 2005; 109(3): 243-56.
73. [73] Steppan CM, Wang J, Whiteman EL, Birnbaum MJ, Lazar MA. Activation of SOCS-3 by resistin. Mol Cell Biol 2005; 25(4): 1569-75.
74. [74] Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174(9): 5789-95.
75. [75] Bertolani C, Sancho-Bru P, Failli P, et al. Am J Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Pathol 2006; 169(6): 2042-53.
76. [76] Ahmed Murad, Hanan Hassan, Hany Husien, Amro Ayad. Serum resistin level in nonalcoholic fatty liver disease and its relationship to liver disease severity. JEMDSA 2010; 15(1): 53-6.
77. [77] Shen C, Zhao CY, Wang W, et al. The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis. BMC Gastroenterol 2014; 14: 39.
78. [78] Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307(5708): 426-30.
79. [79] Jia SH, Li Y, Parodo J, et al. Pre-B cell colony enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113(9): 1318-27.
80. [80] Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance 2008; 14(11-12): 741-51.
81. [81] Garcia-Diaz D, Campion J, Milagro FI, Martinez JA. Adiposity dependent apelin gene expression: relationships with oxidative and inflammation markers. Mol Cell Biochem 2007; 305: 87-94.
82. [82] Principe A, Melgar-Lesmes P, Fernandez-Varo G, et al. The hepatic apelin system: a new therapeutic target for liver disease. Hepatology 2008; 48: 1193-201.
83. [83] Ercin CN, Dogru T, Tapan S, et al. Plasma apelin levels in subjects with nonalcoholic fatty liver disease. Metabolism 2010; 59(7): 977-81.
84. [84] Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor super families: integrating mammalian biology. Cell 2001; 104(4): 487-501.
85. [85] Hotamisligil GS. The role of TNF alpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999; 245(6): 621-25.
86. [86] Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNFalpha function. Nature 1997; 389(6651): 610-14.
87. [87] Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumornecrosisfactoralphapromoterpolymorphisms and insulinresistance in nonalcoholicfattyliverdisease. Gastroenterology 2002; 122(2): 274-80.
88. [88] Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27(5): 412-21.
89. [89] Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54.
90. [90] Abiru S, Migita K, Maeda Y, et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 2006; 26: 39-45.
91. [91] Satapathy SK, Garg S, Chauhan R, et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 1946-52.
92. [92] Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37(2): 343-50.
93. [93] Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115(5): 911-9.
94. [94] Jin X, Zimmers TA, Perez EA, Pierce RH, Zhang Z, Koniaris LG. Paradoxical effects of shortand long-term interleukin-6 exposure on liver injury and repair. Hepatology 2006; 43(3): 474-84.
95. [95] Kumar R, Prakash S, Chhabra S, et al. Association of proinflammatory cytokines, adipokines & oxidative stress with insulin resistance & non-alcoholic fatty liver disease. Indian J Med Res 2012; 136(2): 229-36.
96. [96] García-Galiano D, Sánchez-Garrido MA, Espejo I, et al. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and nonalcoholic steatohepatitis in morbidly obese patients. Obes Surg 2007; 17(4): 493-503.
97. [97] Mas E, Danjoux M, Garcia V, Carpentier S, Ségui B, Levade T. IL6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. PLoS One 2009; 4(11): 7929.